Tuesday, October 27, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 26, 2026

Crypto News: Pepeto DeFi Project Crosses $9,575,434 Raised While Bitcoin Price Prediction Reaches $300,000 to $500,000

View original at globenewswire.com
“Strategy backed that view with cash, adding 34,164 BTC for $2.54 billion at $74,395, its largest buy since 2024”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • High-profile endorsements of Pepeto are circulating in private Telegram and group channels but remain unconfirmed

    60% confidence
  • Strategy's Bitcoin holdings are showing a profit for the first time in months against a $75,527 average cost across 815,061 coins

    60% confidence
  • Bitcoin price is $78,060

    60% confidence
  • Strategy's total BTC holdings are 815,061 coins with an average cost basis of $75,527 per coin

    60% confidence
  • Strategy's $2.54 billion BTC purchase was its largest buy since 2024

    60% confidence
  • Bitcoin will reach between $300,000 and $500,000 by late 2029 based on historical cycle patterns

    60% confidence
  • Global crypto funds recorded $1.4 billion in inflows last week, the strongest inflow week since January

    60% confidence
  • Bitcoin will form an investable low in late 2026 before beginning a parabolic climb

    60% confidence
  • Bitcoin is up over 13% this month and tracking its best monthly close in a year

    60% confidence
  • Pepeto features a zero-fee exchange, cross-chain bridge across Ethereum, BNB Chain, and Solana, an AI contract scanner, and 178% APY staking, all audited by SolidProof

    60% confidence

Data points we hold from this source

Pepeto · revenue9575434 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Crypto News: Pepeto DeFi Project Crosses $9,575,434 Raised While Bitcoin Price Prediction Reaches $300,000 to $500,000 — Source | Via News | ViaNews Market